Cerity Partners LLC Takes Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Cerity Partners LLC purchased a new stake in shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 517,581 shares of the company’s stock, valued at approximately $1,661,000.

Other institutional investors have also recently made changes to their positions in the company. Great West Life Assurance Co. Can raised its stake in shares of Allogene Therapeutics by 26.1% during the 1st quarter. Great West Life Assurance Co. Can now owns 8,827 shares of the company’s stock valued at $43,000 after purchasing an additional 1,826 shares during the period. Ensign Peak Advisors Inc raised its stake in shares of Allogene Therapeutics by 11.3% during the 3rd quarter. Ensign Peak Advisors Inc now owns 20,910 shares of the company’s stock valued at $226,000 after purchasing an additional 2,120 shares during the period. WINTON GROUP Ltd raised its stake in shares of Allogene Therapeutics by 6.4% during the 1st quarter. WINTON GROUP Ltd now owns 37,255 shares of the company’s stock valued at $184,000 after purchasing an additional 2,251 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Allogene Therapeutics by 1.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 203,865 shares of the company’s stock valued at $1,013,000 after purchasing an additional 2,459 shares during the period. Finally, Oppenheimer & Co. Inc. raised its stake in shares of Allogene Therapeutics by 24.9% during the 1st quarter. Oppenheimer & Co. Inc. now owns 15,050 shares of the company’s stock valued at $137,000 after purchasing an additional 3,000 shares during the period. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Trading Up 0.3 %

Shares of Allogene Therapeutics stock opened at $3.47 on Friday. The firm has a market capitalization of $586.74 million, a PE ratio of -1.66 and a beta of 0.81. The business’s 50-day moving average price is $4.49 and its 200-day moving average price is $3.54. Allogene Therapeutics, Inc. has a 12 month low of $2.23 and a 12 month high of $6.89.

Allogene Therapeutics (NASDAQ:ALLO) last announced its quarterly earnings data on Thursday, March 14th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.04. The firm had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.05 million. Allogene Therapeutics had a negative return on equity of 53.76% and a negative net margin of 202,366.25%. As a group, analysts predict that Allogene Therapeutics, Inc. will post -1.69 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the company. JPMorgan Chase & Co. decreased their price objective on Allogene Therapeutics from $9.00 to $8.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 27th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a research note on Tuesday, March 19th. Guggenheim lowered Allogene Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, January 5th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 target price on shares of Allogene Therapeutics in a research note on Friday, March 15th. Finally, JMP Securities restated a “market perform” rating on shares of Allogene Therapeutics in a research note on Friday, January 5th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.94.

Allogene Therapeutics Company Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).